Dr. Ray Dingledine is Honored with the Robert R. Ruffolo Career Achievement Award
The American Society for Pharmacology and Experimental Therapeutics (ASPET) honored Ray Dingledine with the prestigious "Robert R. Ruffolo Career Achievement Award in Pharmacology". Please join me to congratulate Ray for this wonderful national recognition!
Dr. Raymond J. Dingledine, professor and chair of the department of pharmacology at Emory University School of Medicine, is the recipient of the 2018 ASPET Robert R. Ruffolo Career Achievement Award in Pharmacology.
The Ruffolo Award was established in 2011 in recognition of the contributions made to drug discovery and development by Dr. Ruffolo. The award recognizes the scientific achievements of scientists who are at the height of their careers and who have made significant contributions to pharmacology.
Dr. Dingledine is being recognized for his research achievements on the pharmacology of the glutamate receptors and the causes of epilepsy, including his earlier work that provided insight into the regulation of postsynaptic glutamate receptors, and his more recent studies that led to the identification of novel EP2 prostaglandin receptor antagonists. He was nominated by Dr. John S. Lazo from University of Virginia School of Medicine, who noted that Dr. Dingledine “shares with Dr. Ruffolo an appreciation of high throughput methods, a deep respect for the power of quantitative pharmacologic methods, and a bent towards drug discovery.”
Dr. Dingledine received his PhD in pharmacology from Stanford University in 1975. He spent time at the University of Cambridge, the University of Oslo, The Salk Institute, and the University of North Carolina at Chapel Hill before joining Emory University School of Medicine in 1992, where he currently chairs the pharmacology department.
Dr. Dingledine’s research focuses on the pharmacology of glutamate receptors and the causes of epilepsy. His early work provided numerous seminal insights into the regulation of postsynaptic glutamate receptors. Some of these findings led him to co-found NeurOp, Inc., a company focused on novel therapeutics for neurological disorders. His recent work has led to the identification of novel EP2 prostaglandin receptor antagonists capable of reducing neuroinflammation, with these studies revealing diverse immunomodulation pathways in epilepsy.
Dr. Dingledine has published over 200 research papers during his career. An ASPET member for 35 years, he has served as editor of Molecular Pharmacology and on the editorial board of Molecular Interventions and currently serves on the ASPET Investment Subcommittee.
Over the years, Dr. Dingledine has been recognized for numerous awards, including the ASPET Epilepsy Research Award in 1991 and election to the National Academy of Medicine in 2010.
ASPET will present Dr. Dingledine with the Ruffolo award during the ASPET Annual Meeting at Experimental Biology 2018 in San Diego, CA on Saturday, April 21, 2018 from 4:30 pm – 6:00 pm
